{"altmetric_id":15777943,"counts":{"readers":{"mendeley":17,"citeulike":0,"connotea":0},"total":{"posts_count":1},"policy":{"unique_users_count":1,"unique_users":["nice"],"posts_count":1}},"citation":{"altmetric_jid":"4f6fa4eb3cf058f61000282a","authors":["A. Messori","S. Trippoli","P. Becagli","M. Cincotta","M. G. Labbate","G. Zaccara"],"doi":"10.1007\/s002280050402","endpage":"427","first_seen_on":"2017-01-25T14:15:39+00:00","handles":[],"isbns":[],"issns":["0031-6970","1432-1041"],"issue":"6","journal":"European Journal of Clinical Pharmacology","last_mentioned_on":1382054400,"links":["http:\/\/dx.doi.org\/10.1007\/s002280050402"],"pdf_url":"http:\/\/link.springer.com\/content\/pdf\/10.1007%2Fs002280050402.pdf","pubdate":"1998-03-06T00:00:00+00:00","publisher":"Springer-Verlag","publisher_subjects":[{"name":"Pharmacology And Pharmaceutical Sciences","scheme":"era"}],"scopus_subjects":["Health Sciences","Medicine","Life Sciences","Pharmacology, Toxicology and Pharmaceutics"],"startpage":"421","title":"Adjunctive lamotrigine therapy in patients with refractory seizures: a lifetime cost-utility analysis","type":"article","uri":"http:\/\/link.springer.com\/10.1007\/s002280050402","volume":"53","mendeley_url":"http:\/\/www.mendeley.com\/research\/adjunctive-lamotrigine-therapy-patients-refractory-seizures-lifetime-costutility-analysis"},"altmetric_score":{"score":3,"score_history":{"1y":0,"6m":0,"3m":0,"1m":0,"1w":0,"6d":0,"5d":0,"4d":0,"3d":0,"2d":0,"1d":0,"at":3},"context_for_score":{"all":{"total_number_of_other_articles":7030920,"mean":6.2656066980691,"rank":1650033,"this_scored_higher_than_pct":64,"this_scored_higher_than":4555593,"rank_type":"exact","sample_size":7030920,"percentile":64},"similar_age_3m":{"total_number_of_other_articles":88818,"mean":11.134233739037,"rank":26950,"this_scored_higher_than_pct":67,"this_scored_higher_than":60312,"rank_type":"exact","sample_size":88818,"percentile":67},"this_journal":{"total_number_of_other_articles":856,"mean":4.1821122807018,"rank":198,"this_scored_higher_than_pct":47,"this_scored_higher_than":409,"rank_type":"exact","sample_size":856,"percentile":47},"similar_age_this_journal_3m":{"total_number_of_other_articles":10,"mean":3.9,"rank":5,"this_scored_higher_than_pct":50,"this_scored_higher_than":5,"rank_type":"exact","sample_size":10,"percentile":50}}},"demographics":{"users":{"mendeley":{"by_status":{"Researcher":3,"Student  > Doctoral Student":3,"Student  > Ph. D. Student":1,"Student  > Postgraduate":1,"Other":3,"Student  > Master":3,"Professor":3},"by_discipline":{"Medicine and Dentistry":6,"Social Sciences":2,"Immunology and Microbiology":1,"Economics, Econometrics and Finance":2,"Unspecified":3,"Pharmacology, Toxicology and Pharmaceutical Science":3}}}},"posts":{"policy":[{"title":"Enzalutamide for metastatic hormone\u2011relapsed prostate cancer previously treated with a docetaxel\u2011containing regimen: Prostate cancer (hormone relapsed, metastatic) - enzalutamide (after docetaxel): evaluation report","url":"https:\/\/www.nice.org.uk\/guidance\/TA316\/documents\/prostate-cancer-hormone-relapsed-metastatic-enzalutamide-after-docetaxel-evaluation-report4","license":"public","citation_ids":[173633,950828,212088,210391,4323065,15778003,1145378,15777869,15777870,173633,21717080,15777878,21717082,15777883,15777885,21717086,15777891,15777895,15777898,13458628,15777904,15777909,733418,811651,15777914,22864529,5741634,15777924,3205328,6337288,5318216,2475799,13253051,828727,7410183,15777932,2412850,21717093,15777933,15777936,1644797,15777943,15777948,15299441,15777390,15777955,2416454,15777958,15777962,2475752,5763698,15777966,15777971,21717099,15777974,15777235,21717100,21717103,21717108,21717112,21717114,15777987,3638564,5482878,1486073,4323582,211959,3077654,212088,15778006,15022941,3096223,5730020,950828,15778018,840247,21717121,406418,4950539,4111073,6096556,439560,3174146,15778028,9850347],"posted_on":"2013-10-18T00:00:00+00:00","source":{"name":"National Institute for Health and Care Excellence","description":"The National Institute for Health and Care Excellence (NICE) in the UK provides national guidance and advice to improve health and social care.","geo":{"country":"GB"}},"page_url":"https:\/\/www.nice.org.uk\/guidance\/ta316\/evidence","collections":[],"author":{"image":"https:\/\/s3.amazonaws.com\/cache.altmetric.com\/policy\/thumbnails\/thumbnail-8a92b7ec61cbefe52352249a2431bb61eb48b81ec68c2139b4c70b0ca0895fa4.jpg"}}]}}